CSIMarket
 
Mainz Biomed N v   (NASDAQ: MYNZ)
Other Ticker:  
 
 
Price: $6.5300 $-1.05 -13.852%
Day's High: $7.8 Week Perf: -11.88 %
Day's Low: $ 5.95 30 Day Perf: 23.44 %
Volume (M): 601 52 Wk High: $ 45.60
Volume (M$): $ 3,927 52 Wk Avg: $18.82
Open: $7.53 52 Wk Low: $3.65



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 0
 Employees 120
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) 17
 Capital Exp. (TTM) (Millions $) 1

Mainz Biomed N V
Mainz Biomed N v is a pharmaceutical company located in Mainz, Germany. The company focuses on biomedicine and specializes in the research, development, and production of innovative drugs and medical treatments. They aim to improve patient health and quality of life through their scientific advancements. Mainz Biomed N v also collaborates with academic institutions and other pharmaceutical companies to foster innovation and bring cutting-edge therapies to market. They prioritize patient safety, efficacy, and accessibility in their product development process.


   Company Address: Mainz Biomed N.V. Mainz 55129
   Company Phone Number: 6131 / 55428-60   Stock Exchange / Ticker: NASDAQ MYNZ


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACUT        10.34% 
OBMP        155.7% 
COIN        1.53% 
EXAS   -5.49%    
GH        7.57% 
• View Complete Report
   



Partnership

Pioneering Colorectal Cancer Screening Mainz Biomed Partners with Quest Diagnostics to Enhance Clinical Trials

Published Thu, Dec 19 2024 1:01 PM UTC

Mainz Biomed, an innovative biotechnology company focused on the development of solutions for colorectal cancer detection, has announced a significant agreement with Quest Diagnostics. This partnership aims to provide essential clinical trials laboratory services that will bolster the development of Mainz Biomed?s groundbreaking screening test.Colorectal cancer is one of the...

Stock Market Announcement

Mainz Biomed Takes a Strategic Leap: Harnessing AI for Breakthrough Diagnostics Amid New Funding

Published Fri, Dec 13 2024 1:00 AM UTC

In a significant development within the biopharmaceutical landscape, Mainz Biomed, a dedicated player in the field of molecular genetic testing, has announced the completion of an $8.0 million follow-on offering priced under the at-the-market (ATM) provisions of Nasdaq rules. This financial move comes on the heels of the company s recent unveiling of a strategic initiative a...

Management Announcement

A New Era in Diagnostics: Mainz Biomeds Strategic Leap Towards AI-Enhanced Biomarker Discovery and FDA Trials

Published Tue, Oct 1 2024 12:01 PM UTC

In the ever-evolving landscape of healthcare, the integration of artificial intelligence (AI) has become a cornerstone of innovation, particularly in the challenging field of cancer diagnostics. Mainz Biomed N.V. (NASDAQ: MYNZ) stands at the forefront of this transformation, spearheading advancements aimed at early detection and management of pancreatic diseases through its ...

Partnership

Harnessing AI for Enhanced Biomarker Selection Mainz Biomeds Strategic Partnership with Liquid Biosciences

Published Wed, Sep 4 2024 8:01 AM UTC

Abstract Artificial Intelligence (AI) has emerged as a pivotal tool in pharmaceutical sciences, particularly in the realm of biomarker discovery. In this context, Mainz Biomed N.V. (NASDAQ: MYNZ) has announced a strategic partnership with Liquid Biosciences aimed at leveraging AI to enhance the selection and optimization of biomarkers for its PancAlert platform. This develop...

Product Service News

In a significant stride toward optimizing colon cancer screening, Mainz Biomed recently unveiled the latest...

Published Thu, Jul 25 2024 12:01 PM UTC

Enhanced ColoAlert: Mainz Biomed Revolutionizes Colon Cancer Screening with Advanced Features and Unmatched User Convenience In a significant stride toward optimizing colon cancer screening, Mainz Biomed recently unveiled the latest iteration of its flagship product, ColoAlert. Emphasizing remarkable advancements in screening efficiency and user convenience, the enhanced Col...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com